2017 Virtual Symposium (Expired): Closing the Gap Created by Clinical Inertia: New Strategies for T2DM Treatment

The prevalence of T2DM in the United States is 29.1 million and it is the seventh leading cause of death and a major cause of morbidity, including microvascular, macrovascular, cerebrovascular, and peripheral vascular disease complications. The goal of this symposium is to increase awareness among clinicians of the challenges in reaching T2DM glycemic targets, to review the clinical guidelines for T2DM treatment using an array of antihyperglycemic agents, and to present evidence on emerging basal insulin/GLP-1RA fixed-ratio combination products.

Source:2017 Virtual Symposium (Expired): Closing the Gap Created by Clinical Inertia: New Strategies for T2DM Treatment